| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000045 | Autophagosome assembly | Increases phenotype | PMID:31020377 |
| GO:0001825 | Blastocyst formation | Decreases phenotype | PMID:27417426 |
| GO:0002440 | Production of molecular mediator of immune response | Increases phenotype | PMID:18995849 |
| GO:0002523 | Leukocyte migration involved in inflammatory response | Increases phenotype | PMID:36450500 |
| GO:0004784 | Superoxide dismutase activity | Decreases phenotype | PMID:31251971 |
| GO:0006590 | Thyroid hormone generation | Affects phenotype | PMID:36450500 |
| GO:0006750 | Glutathione biosynthetic process | Decreases phenotype | PMID:31251971 |
| GO:0006914 | Autophagy | Increases phenotype | PMID:31020377; PMID:32895711 |
| GO:0007005 | Mitochondrion organization | Decreases phenotype | PMID:36450500 |
| GO:0007058 | Spindle assembly involved in female meiosis ii | Decreases phenotype | PMID:31388691 |
| GO:0007612 | Learning | Affects phenotype | PMID:32521479 |
| GO:0008283 | Cell population proliferation | Increases phenotype | PMID:31251971 |
| GO:0009566 | Fertilization | Decreases phenotype | PMID:31388691 |
| GO:0010942 | Positive regulation of cell death | Increases phenotype | PMID:27417426 |
| GO:0016049 | Cell growth | Decreases phenotype | PMID:29704545 |
| GO:0019659 | Glucose catabolic process to lactate | Increases phenotype | PMID:31251971 |
| GO:0030500 | Regulation of bone mineralization | Affects phenotype | PMID:23816203 |
| GO:0032204 | Regulation of telomere maintenance | Affects phenotype | PMID:32300848 |
| GO:0032237 | Activation of store-operated calcium channel activity | Increases phenotype | PMID:32895711 |
| GO:0032776 | Dna methylation on cytosine | Affects phenotype | PMID:31388691 |
| GO:0033327 | Leydig cell differentiation | Decreases phenotype | PMID:27417426 |
| GO:0040038 | Polar body extrusion after meiotic divisions | Decreases phenotype | PMID:31388691 |
| GO:0042403 | Thyroid hormone metabolic process | Affects phenotype | PMID:19750101 |
| GO:0043433 | Negative regulation of dna-binding transcription factor activity | Increases phenotype | PMID:26022396 |
| GO:0044027 | Hypermethylation of cpg island | Affects phenotype | PMID:25585924 |
| GO:0044237 | Cellular metabolic process | Increases phenotype | PMID:31251971 |
| GO:0045821 | Positive regulation of glycolytic process | Increases phenotype | PMID:30821169 |
| GO:0046330 | Positive regulation of jnk cascade | Increases phenotype | PMID:26519956 |
| GO:0050847 | Progesterone receptor signaling pathway | Decreases phenotype | PMID:26022396 |
| GO:0050890 | Cognition | Decreases phenotype | PMID:18288320; PMID:20731829 |
| GO:0051091 | Positive regulation of dna-binding transcription factor activity | Increases phenotype | PMID:26022396 |
| GO:0061370 | Testosterone biosynthetic process | Decreases phenotype | PMID:27417426 |
| GO:0070192 | Chromosome organization involved in meiotic cell cycle | Decreases phenotype | PMID:31388691 |
| GO:0070327 | Thyroid hormone transport | Decreases phenotype | PMID:25644787 |
| GO:0071407 | Cellular response to organic cyclic compound | Affects phenotype | PMID:26022396; PMID:32199159 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:36450500 |
| GO:0090116 | C-5 methylation of cytosine | Decreases phenotype | PMID:31388691 |
| GO:1900017 | Positive regulation of cytokine production involved in inflammatory response | Increases phenotype | PMID:26519956 |
| GO:1901522 | Positive regulation of transcription from rna polymerase ii promoter involved in cellular response to chemical stimulus | Increases phenotype | PMID:26022396 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:30821169; PMID:31251971 |
| GO:1904613 | Cellular response to 2,3,7,8-tetrachlorodibenzodioxine | Increases phenotype | PMID:26022396 |
| GO:2000020 | Positive regulation of male gonad development | Decreases phenotype | PMID:27417426 |
| GO:2000612 | Regulation of thyroid-stimulating hormone secretion | Affects phenotype | PMID:19750101 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.